Answers are grounded in this paper and cite their sources.
Here, we developed a straightforward methodology to generate TCRαβ negative (allogeneic) cells for CAR-T cell therapies. With an early and transient expression of an anti-CD3 CAR in the engineered donor T cells, we programed these cells to self-eliminate the TCR+ cell population and obtained an ultrapure TCRαβ- population (99%-99.9%) at the end of the CAR-T production. This novel and easy-to-implement procedure preserves the production yield and cell fitness and has the potential to streamline the manufacturing of “off-the-shelf” CAR T-cell therapies.
No takes yet. Share an insight, caveat, or question.
Juillerat et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: